PCSK9 and metabolic syndrome: From our point of view, in the case of Spain, it is very important to improve the treatment of dyslipidemia with statins and other drugs because the new treatments, such as PCSK9 inhibitors or, in the future, inclisiran and evinacumab, are restricted only to hospital treatment in patients with very high risk and that do not reach <100 mg/dL.